DOCSLIB.ORG

Method and Compositions for the Treatment of Tumors Comprising a Calcium Channel Blocker Compound of the Dlhydropyridlne Class and a Platinum Coordination Compound

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Method and Compositions for the Treatment of Tumors Comprising a Calcium Channel Blocker Compound of the Dlhydropyridlne Class and a Platinum Coordination Compound turopaiscnes patentamt European Patent Office © Publication number: 0 221 382 Office europeen des brevets A1 (2) EUROPEAN PATENT APPLICATION © Application number: 86113897.2 © Int. CI.4: A61K 33/24 , ~ //(A61K33/24,31:44) © Date of filing: 07.10.86 © Priority: 10.10.85 US 786321 © Applicant: THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY © Date of publication of application: 5050 Cass Avenue 13.05.87 Bulletin 87/20 Detroit Michigan 48202(US) © Designated Contracting States: @ Inventor: Honn, Kenneth V. AT BE CH DE ES FR GB IT LI LU NL SE 1889 Stanhope Grosse Polnte Woods, Michigan 48236(US) Inventor: Tayior, John D. 1408 Joliet Place Detroit, Michigan 48207(US) Inventor: Onoda, James M. 212 Baker Street No. 203, Royal Oak, Michigan 48067(US) © Representative: Patentanwalte GrUnecker, Kinkeidey, Stockmalr & Partner Maximllianstrasse 58 D-8000 MUnchen 22(DE) «y Method and compositions for the treatment of tumors comprising a calcium channel blocker compound of the dlhydropyridlne class and a platinum coordination compound. (jy The invention relates to compositions for the vherein R, and R2 are methyl groups, R, and R» are treatment of malignant tumors in a mammal which ilkyi or alkyloxyalkylene groups containing I to 8 comprise: :arbdn atoms and R5 and R« are hydrogen or one or (a) a calcium channel blocker compound of wo electron withdrawing substituents; and the dihydropyridine class selected from the group (b) a platinum coordination compound which ^consisting of las antitumor properties in humans wherein the veight ratio of the calcium channel blocker com- x>und to the platinum coordination compound is >etween I and 1000 and 10 to I. Furthermore, the invention relates to a method or the treatment of malignant tumors in vitro by idministering the afore-mentioned compositions. u arm Copy Centre 0 221 382 FIG. I Cisplatin Effects on B I 6a Proliferation 251 normal CPR-0.25 CPR-5.0 CO «J Ll 004 CO "3 O c_ 75i o E 501 c o O 251 AM 1 0 <?*> 0r O' Cisplatin CpM) 1a 1 0 221 382 2 Mb I rtuu AND COMPOSITIONS FOR THE TREATMENT OF TUMORS COMPRISING A CALCIUM CHANNEL BLOCKER COMPOUND OF THE DIHYDROPYRIDINE CLASS AND A PLATINUM COORDINATION COM- POUND tastases prevents cisplatin chemotherapy from Cross-Reference to Related Application achieving partial or complete remission rates of more than 15% to 70% for testicular cancer (Stoter The present invention is a continuation-in-part et al, Cancer 54:1521, 1984), and ovarian cancer - of application Serial No. 480,704, filed March 31, 5 (Belinson et al., Cancer 54:1983, 1984), and 30-40% I983 which has inventors in common with this ap- for cancer of the head and neck (Wittes et al., plication and is assigned to a common assignee. Cancer Treat. Rep. 63:1533, 1979). The most serious problem encountered in the chemotherapeutic treatment of cancer is the pres- BACKGROUND OF THE INVENTION io ence and/or the development of drug resistance by cells of the primary tumor. If the patient dies of (I) Field of Jhe. Invention metastatic cancer, the cells of the metastatic foci are usually also characterized by their extreme The present invention relates to a method and resistance to single or combinations of the avail- compositions for the treatment of malignant tumors 75 able chemotherapeutic drugs. In general, drug re- or metastasis of malignant tumors by administering sistant tumor ceils simply accumulate less (a sub- a platinum coordination compound and a calcium lethal dose) of the chemotherapeutic drug(s) than channel blocker compound of the dihydropyridine do cells which succumb to the therapeutic agent. class. In particular the present invention relates to a Drug resistant tumors can be classified as tem- method which comprises administering cis-diam- 20 porary or permanent (DeVlta, V.T., Cancer 51:1209, minedichloroplatinum (II) and nifedipine, respective- 1983). Temporary drug resistant tumors are thought ly, as the compounds. to be resistant as a result of physiological factors such as sublethal exposure to drug by tumor cells distant from circulation (i.e., perfusion barrier; Suth- (Z) Prior Art 25 erland, R. M., et al., J. Nat. Cancer Inst. 46:113, 1971; and West, G.W., et al., Cancer Res. 40:3665, 1980). Cis-diamminedichloroplatinum (CDDP, Additionally, it has been suggested that the overall cisplatin) is the first inorganic antitumor agent used growth kinetics of the tumor (Shackney, S.E., et al., for clinical cancer therapy. Developed and first Ann. Int. Med. 89:107, 1978) are an important factor described by Rosenberg et al (Nature 205:698, - 30 in temporary tumor cell resistance (i.e., slowly or (I965); Nature 222:385, (I969)), cisplatin has proven asynchronously growing tumor cells would be less to be an effective antineoplastic agent not only likely to be exposed to (accumulate) bolus injected against germinal neoplasms as it was first utilized - anticancer agents). Permanent drug resistant tumor (Einhorn et al., Int. Med. 87:293, I977) but also cells are thought to arise spontaneously, and their against bladder and ovarian cancer and cancer of 35 probability of existence may be related to tumor the head and neck. It is possible that cisplatin mass and/or age. The concept of the spontaneous alone or cisplatin in combination with other an- genetic origin of drug resistant neoplasms (Goldie tineoplastic drugs (e.g., adriamycin, vincristine, and Coldman, Cancer Res. 44:3643, 1984) and tu- etc.) may become the accepted standard agent for mor heterogeneity in terms of metastatic potential - the chemotherapeutic treatment of a majority of 40 (Fidler, I. J., Cancer Res. 38:2651, 1978) and drug malignancies including those which are usually sensitivity (Tanigawa, N, et al., Cancer Res. considered non-responsive to chemotherapy, such 44:2309, 1984), has gained widespread acceptance as estrogen resistant prostate carcinoma (Merrin, as the mechanism of permanent tumor cell resis- C.E., Cancer Treat. Rep. 63:1579, 1979). This and tance. The two principal mechanisms of permanent other platinum coordination compounds are shown 45 drug resistance have been found to be mediated in U.S. Patent Nos. 4,140,707, 4,177,263 and by changes in the concentration or activity of an 4,419,351 for instance. enzyme in the resistant cells that "inactivates" the Unfortunately, the development of cisplatin re- drug (Bakka, A., et al., Toxicol. Applied Pharmacol. sistance in malignant tumors which initially re- 61:215, 1981) or by changes in the plasma membrane sponded to cisplatin is an all too often encountered so of the resistant cells which decreases cellular accu- problem (Lee et al., Cancer Treat. Rev. 10:39, 1983). As with other chemotherapeutic drugs, cisplatin resistance of the primary tumor and recurrent me- > 3 0 221 382 4 mulation of drug by inhibiting drug influx and/or by sults in a decrease in the LD50 concentration of the increasing the rate of drug efflux (Giavazzi, R, et antitumor agent. The ability of daunorubicin resis- al., Cancer Res. 43:2216, 1983; Yanovich, S., et al., tant and sensitive Ehriich ascites carcinoma cells to Cancer Res. 44:1743, 1984). accumulate and retain daunorubicin is inversely Initial attempts to circumvent drug resistance 5 related to the concentration of Ca2+ in the incuba- centered on alterations in the scheduling, dosages, tion medium (Murray et al, Cancer Chemotherap. and/or method of application of a single Pharmacol. 13:69, 1984). Verapamil's ability to in- chemotherapeutic agent (Benz, C, et al., Cancer crease daunorubicin cytotoxicity in resistant Ehriich Res. 42:2081, 1982; Ozols, R. F., et al., Cancer Res. tumor cells may be at least partially attributable to 42:4265, 1982). Much more promising, however, 10 its (verapamil) ability to inhibit calcium influx, which appears to be combined drug therapy using would have effects similar to those obtained by cytotoxic agents with different mechanisms of ac- decreasing extracellular CaJ+. tion. This type of therapy has improved the cure The cytotoxic mechanism of action of cisplatin rate for some cancers but the ultimate failure of is known to be its ability of the platinum moiety to even this strategy is well documented (Ling, V., et is form. DNA-DNA and DNA-protein crosslinks in the al., Cancer Treat. Rep. 67:869, 1983; Citrin, D. L, et target cell nucleus, thus preventing new mRNA al., Cancer 50:201, 1982). transcription and DNA replication (Roberts, J. J., In: Recently, a new methodology has been sug- Molecular Actions and Targets for Cancer gested which may be of great benefit in the Chemotherapeutic Agents, Academic Press, New chemotherapeutic treatment of cancer. This meth- 20 York, p. 17, I98I). The exact mechanism of resis- odology is centered on the use of agents which tance to cisplatin, however, is not known (Curt et al, function to enhance the initial kill-rate of a cytotoxic Cancer Treat. Rep. 68:87, I984). Sigdestad et al - drug and/or which enhance the ability of the drug (Cancer Treat. Rep. 65:845, I98I) reported that all to overcome drug resistant tumors. phases of the cell cycle (Gl, S, G2 and M) of a Inaba, M., et al., Cancer Res. 39:2200, 1979 25 murine fibrosarcoma were sensitive (in vivo) to reported that the significantly decreased uptake cisplatin although cells in the Gl phase were the and retention of adriamycin and daunorubicin by most sensitive by a factor of 10. This data suggests P388 leukemia cells resistant to these agents was that slowly growing cells or asynchronously grow- mediated by an active outward transport of the two ing tumor cells might be the population of cells that cytotoxic agents by resistant cells. These findings 30 eventually demonstrate cisplatin resistance. Wheth- suggested that membrane active compounds might er the growth rate or phase of cell cycle affects be utilized to overcome the outward transport of enzyme activity or the membrane of resistant cells cytotoxic agents from resistant tumor cells.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Phase II Trial of VELCADE® (Bortezomib)
    Phase II Trial of VELCADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme. Protocol Version: Date of Protocol: Original January 22, 2009 Amendment 1 February 14, 2011 Amendment 2 May 31, 2012 Amendment 3 August 1, 2012 Amendment 4 January 09, 2013 Amendment 5 March 13, 2013 Amendment 6 November 19, 2013 Amendment 7 February 11, 2014 Principal Investigator Dr. Albert Lai University of California at Los Angeles VELCADE (bortezomib) for Injection UCLA STUDY PROTOCOL Protocol Number X05303 Phase II Trial of VELCADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme. Protocol Version: Date of Protocol: Original January 22, 2009 Amendment 1 February 14, 2011 Amendment 2 May 31, 2012 Amendment 3 August 1, 2012 Amendment 4 January 09, 2013 Amendment 5 March 13, 2013 Amendment 6 November 19, 2013 Amendment 7 February 11, 2014 Investigator &Study Center: Principal Investigator Co-Principal Investigator Sub-Investigators Sub-Site: *VELCADE is the exclusive trademark of Millennium Pharmaceuticals, Inc., registered in the United States and internationally. CONFIDENTIAL Page 1 of 86 Amendment 7 version dated February 11, 2014 VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program PROTOCOL SUMMARY Title: Phase II Trial of VELCADE* (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme. Objectives: This phase II study will examine the safety and efficacy of bortezomib in combination with temozolomide/radiation followed by bortezomib and temozolomide for 2 years (24 28-day cycles) in newly-diagnosed patients with glioblastoma.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Sustained-Release Dihydropyridine Formulation
    Europaisches Patentamt European Patent Office ® Publication number: 0 231 026 Office europeen des brevets A1 EUROPEAN PATENT APPLICATION @ Application number: 87101203.5 © lnt.CI.": A 61 K 31/44 A 61 K 9/16, A 61 K 9/22 @ Date of filing: 29.01.87 © Priority: 30.01.86 US 823896 10.12.86 US 940878 ® Applicant: SYNTEX (U.S.A.) INC. 3401 Hillview Avenue P.O. Box 10850 © Date of publication of application : Palo Alto California 94303 (US) 05.08.87 Bulletin 87/32 @ Inventor: Macfarlane, Calum Brechin © Designated Contracting States: Callater House Champfleurie AT BE CH DE ES FR GB GR IT LI LU NL SE Linthgow EH49 6NB Scotland (GB) Selkirk, Alastair Brereton 14 Cramond Glebe Gardens Edinburgh Scotland (GB) Dey, Michael John 17 Ormiston Drive East Calder West Lothian Scotland (GB) @ Representative: Barz, Peter, Dr. et al Patentanwalte Dipl.-lng. G. Dannenberg Dr. P. Weinhold, Dr. D. Gudel Dipl.-lng. S. Schubert, Dr. P. Barz Siegfriedstrasse 8 D-8000 Munchen 40 (DE) The title of the invention has been amended (Guidelines for Examination in the EPO, A-lll, 7.3). © Sustained-release dihydropyridine formulation. © A long acting sustained release pharmaceutical composi- tion for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter. CO CM o CO CM O. LU Bundesdruckerei Berlin 0 231 026 Description LONG ACTING FORMULATION This invention concerns long acting sustained releas i pharmaceutical compositions and dosage forms for dihydropyridine calcium channel blockers.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Dihydropyridine Receptor in Rat Brain Labeled With
    Proc. Nati. Acad. Sci. USA Vol. 80, pp. 2356-2360, April 1983 Medical Sciences Dihydropyridine receptor in rat brain labeled with [3H]nimodipine* (calcium antagonists/binding site/structural specificity/stereoselectivity/cerebrovascular diseases) P. BELLEMANN, A. SCHADE, AND R. TOWARTt Department of Pharmacology, Bayer AG, P.O. Box 10 17 09, D-5600 Wuppertal, Federal Republic of Germany Communicated by Helmut Beinert, December 20, 1982 ABSTRACT Receptor binding sites for 1,4-dihydropyridine potent analogue of nifedipine with cerebrovascular and neuro- (DHP) calcium antagonists have been characterized by using [3H]- and psychopharmacological actions (15, 16). nimodipine, a potent analogue of nifedipine with cerebrovascular and neuro- and psychopharmacological properties. [3H]Nimodi- MATERIALS AND METHODS pine exhibited reversible and saturable binding to partially pu- rified brain membranes. The equilibrium dissociation constant, Materials. [3H]Nimodipine (New England Nuclear) had a Kd, was 1.11 nM and the maximal binding capacity, Bma, was 0.50 specific activity of 160-180 Ci/mmol (1 Ci = 3.7 X 101 Bq) pmol/mg of protein. The DHP receptor proved to be highly spe- and its purity was continuously monitored by thin-layer radio- cific for various potently displacing DHP derivatives and discrim- chromatography. The ligand was stored light-protected (-300C) inated between their optical isomers (stereoselectivity) with in- under nitrogen gas to prevent radiolysis and oxidation. hibition constants (Ki) in the nanomolar or even subnanomolar The DHP derivatives nifedipine, nimodipine, niludipine, range. Structurally different calcium antagonists such as gallo- nisoldipine, nitrendipine, and BAY E 6927, the stereoisomers pamil (D-600), on the other hand, displayed much lower affinities, (Bayer AG, Wuppertal, Federal Republic of Germany), and further substantiating the specificity of the receptor for DHP calcium entry blockers or vasodilators without DHP structure structures.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Quantitative Structure-Interaction Relationship Analysis of 1,4-Dihydropyridine Drugs in Concomitant Administration with Grapefruit Juice
    ORIGINAL ARTICLES Clinical Pharmaceutics Laboratory, Department of Pharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan Quantitative structure-interaction relationship analysis of 1,4-dihydropyridine drugs in concomitant administration with grapefruit juice Y. Uesawa, K. Mohri Received July 11, 2011, accepted August 16, 2011 Dr. Yoshihiro Uesawa, Clinical Pharmaceutics Laboratory, Department of Pharmaceutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan [email protected] Pharmazie 67: 195–201 (2012) doi: 10.1691/ph.2012.1101 Quantitative structure-interaction relationship (QSIR) analyses of 1,4-dihydropyridine drugs were per- formed on grapefruit juice interaction potentials to characterize the interaction and evaluate drugs not yet tested in clinical research. AUC ratios of drugs with and without grapefruit juice ingestion were esti- mated as grapefruit juice interaction potentials from clinical studies on dihydropyridine drugs such as amlodipine, azelnidipine, benidipine, cilnidipine, felodipine, manidipine, nicardipine, nifedipine, nimodip- ine, nisoldipine, and pranidipine. The minimal energy conformation in each dihydropyridine drug was searched for using Merck Molecular Force Field (MMFFaq), and then geometry optimization was performed by density-functional-theory (DFT) calculation (B3LYP/6-31G**). The geometric, electronic, and physico- chemical features including molecular size, dipole moment, total energy, HOMO/LUMO energies, and logP values were then obtained. Dragon descriptors were also calculated by optimized 3D-structures. The rela- tion between the potentials and over 1000 of the molecular properties was investigated using statistical techniques including partial least squares analysis with genetic algorithm (GA-PLS) to a variable subset selection. Some PLS regression equations including logP values and dragon descriptors as explanatory variables were constructed in which the maximal contribution coefficient was 94%.
    [Show full text]
  • Quantitative Structure-Interaction Relationship Analysis of 1,4-Dihydropyridine Drugs in Concomitant Administration with Grapefruit Juice
    ORIGINAL ARTICLES Clinical Pharmaceutics Laboratory, Department of Pharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan Quantitative structure-interaction relationship analysis of 1,4-dihydropyridine drugs in concomitant administration with grapefruit juice Y. Uesawa, K. Mohri Received July 11, 2011, accepted August 16, 2011 Dr. Yoshihiro Uesawa, Clinical Pharmaceutics Laboratory, Department of Pharmaceutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan [email protected] Pharmazie 67: 195–201 (2012) doi: 10.1691/ph.2012.1101 Quantitative structure-interaction relationship (QSIR) analyses of 1,4-dihydropyridine drugs were per- formed on grapefruit juice interaction potentials to characterize the interaction and evaluate drugs not yet tested in clinical research. AUC ratios of drugs with and without grapefruit juice ingestion were esti- mated as grapefruit juice interaction potentials from clinical studies on dihydropyridine drugs such as amlodipine, azelnidipine, benidipine, cilnidipine, felodipine, manidipine, nicardipine, nifedipine, nimodip- ine, nisoldipine, and pranidipine. The minimal energy conformation in each dihydropyridine drug was searched for using Merck Molecular Force Field (MMFFaq), and then geometry optimization was performed by density-functional-theory (DFT) calculation (B3LYP/6-31G**). The geometric, electronic, and physico- chemical features including molecular size, dipole moment, total energy, HOMO/LUMO energies, and logP values were then obtained. Dragon descriptors were also calculated by optimized 3D-structures. The rela- tion between the potentials and over 1000 of the molecular properties was investigated using statistical techniques including partial least squares analysis with genetic algorithm (GA-PLS) to a variable subset selection. Some PLS regression equations including logP values and dragon descriptors as explanatory variables were constructed in which the maximal contribution coefficient was 94%.
    [Show full text]
  • Circumvention of Vincristine and Adriamycin Resistance in Vitro and in Vivo by Calcium Influx Blockers1
    [CANCER RESEARCH 43, 2905-2910, June 1983] 0008-5472/83/0043-0000$02.00 Circumvention of Vincristine and Adriamycin Resistance in Vitro and in Vivo by Calcium Influx Blockers1 Takashi Tsuruo,2 Harumi lida, Makiko Nojiri, Shigeru Tsukagoshi, and Yoshio Sakurai Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170, Japan ABSTRACT In various experimental tumor systems, one of the most im portant mechanisms of drug resistance, especially to Vinca al Calcium influx blockers, diltiazem, nicardipine. nifedipine, nilu- kaloid and anthracycline classes of antitumor agents, has been dipine, and nimodipine, which possess coronary vasodilator ac attributed to the enhanced drug efflux function of the resistant tivity, greatly enhanced the cytotoxicity of vincristine (VCR) in tumor cells (3, 6, 10, 16, 17, 24). These observations suggest tumor cells and especially in VCR-resistant sublines of P388 that if we could control the drug efflux function of tumor cells leukemia (P388/VCR) and human K562 myelogenous leukemia. appropriately, then we could expect anticancer agents to be The extent of enhancement was different among the drugs, and effective against resistant cells (14). We found that the cellular up to a 50- to 70-fold increase in VCR cytotoxicity occurred in calcium may be involved in the drug efflux mechanisms of the P388/VCR cells with nontoxic or marginally toxic concentrations cells (25). Some calcium influx blockers and calmodulin inhibitors of diltiazem and nicardipine. A 50- to 100-fold enhancement efficiently inhibit the VCR3 and ADM efflux function of tumor cells occurred in VCR-resistant human K562 myelogenous leukemia and especially of resistant tumor cells (24-26).
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]